About diaDexus

diaDexus Mission
diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Company Overview
diaDexus was formed in 1997 as a joint venture by SmithKline Beecham and Incyte. SmithKline Beecham granted diaDexus an exclusive license to select diagnostic intellectual property, and Incyte contributed free access to its databases.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

diaDexus' lead product, the PLAC^® Test, measures Lp-PLA₂ (lipoprotein-associated phospholipase A₂) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events.

The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. Over 65 journals and conferences in peer-reviewed articles and abstracts, involving more than 100,000 subjects, highlight Lp-PLA₂ as an important risk factor for cardiovascular disease. For more information regarding the PLAC Test, visit www.plactest.com.